Introduction

Dear colleagues and friends,

Allow us to welcome you to The Hague for the 11th Congress of the European Society of Contraception and Reproductive Health (19-22 May 2010). The time was right to organise an ESC congress in the Netherlands, because we feel that the Dutch have been playing a pivotal role in transforming the ESC from a mainly medical society to a more multidisciplinary European platform where all bio-psycho-social and cultural aspects of contraception and reproductive/sexual health are a focus of interest.

The title of the congress “Culture, Communication, Contraception” reflects that contraceptive and reproductive health care in multicultural Europe must address the different needs of different individuals in different situations. There is a growing requirement for preventive strategies that take into account the specific cultural, sub cultural, economic, ethnic and religious characteristics of subpopulations within the European community. It is the diversity of multicultural Europe that challenges our creativity to provide new solutions, new methods and innovative approaches.

There is no better place in Europe to discuss these topics than the beautiful city of The Hague, which is not only the residence of the Dutch Royal family and the Dutch Government, but also the city were no less than 7 United Nations bodies and numerous headquarters of international organisations reside. The words peace, justice and safety are synonyms for The Hague.

We are confident that the 11th ESC Congress will stay in your memory for a long time.

Rik HW van Lunsen
Congress President

Rob Beerthuizen
Congress President

Congress secretariat

For all information regarding the Society, individual or group registrations, the scientific programme, abstracts, sponsorship, please contact:

ESC Central Office
Opalfeneweg 3
B-1740 Ternat, Belgium
T +32 2 582 08 52
F +32 2 582 55 15
congress@contraception-esc.com
www.contraception-esc.com/thehague.htm

Congress venue

World Forum Convention Center
Churchillplein 10
2517 JW Den Haag
Nederland
www.worldforumcc.com/wfcc/uk

Accommodation

Hotelmatch
T +31 88 0400400
ESC@hotelmatch.nl
www.hotelmatch.nl/ESC_reservation.html
General information

Organisation

Executive Committee of the ESC

J. Bitzer (President)
D. Apter (Vice-President)
S. Randall (Secretary General)
D. Cibula (Assistant Secretary)
M. Lech (Treasurer)
K. Sedlecky (Assistant Treasurer)

Organising Committee

R. Beerthuizen (the Netherlands), Co-President
R.H.W. van Lunsen (the Netherlands), Co-President
F. Roumen (the Netherlands), Vice President
O. Loeber (the Netherlands), Secretary
S. Randall (the Netherlands), Treasurer
M. Lech (Poland), Assistant Treasurer
F. Beerthuizen-Vermeulen (the Netherlands), Member
C. Picavet (the Netherlands), Member
I. Shiripinda (the Netherlands), Member
S. van der Doef (the Netherlands), Member
C. Wijsen (the Netherlands), Member

International Scientific Committee

J.J. Amy (Belgium)
D. Apter (Finland)
I. Batar (Hungary)
D. Baumane – Auza (Latvia)
R. Beerthuizen (the Netherlands)
A. Ber (Israel)
J. Bitzer (Switzerland)
I. Bildar (Romania)
T.A. Carro Bombas (Portugal)
D. Cibula (Czech Republic)
P.G. Crosignani (Italy)
G. Crvenkovic (Croatia)
V. Cupanik (Slovakia)
B. Frey Tirri (Switzerland)
K. Gemzell – Danielsson (Sweden)
H. Guner (Turkey)
M. Kishen (United Kingdom)
D. Lazaris (Greece)
M. Lech (Poland)
I. Le Jeune (Spain)
E. Lopez Arregui (Spain)
C. McNicholas (Ireland)
H. Missey Kolb (France)
F. Mostéou (France)
G. Okoev (Armenia)
P. Patroclou (Cyprus)
B. Pehlivanov (Bulgaria)
K. Petersen (Denmark)
T. Rabe (Germany)
S. Randall (United Kingdom)
N. Salakos (Greece)
H. Satiroglu (Turkey)
K. Sedecky (Serbia)
D. Seidman (Israel)
I. Sivin (USA)
A. Stolfa Gruntar (Slovenia)
M. Tarasova (Russia)
V. Vanagienė (Lithuania)
A. Volpe (Italy)
P. Weiss (Czech Republic)
V. Yaglov (Russia)

The Hague

The Hague, city of many faces

The worldly sophistication of the city centre, the beach and the nightlife sizzle of Scheveningen and the easygoing elegance of Kijkduin, The Hague offers a unique blend of versatility, service and quality. City of 21st century architecture and daring innovations, of both art and business, and most of all, city of style; International style, that is.

Being the Royal residence and the political centre of the Netherlands, the city of The Hague is a national icon. The monumental government buildings, the palaces and the embassies, the fashionable stores, the statues and fountains; they represent the city’s classical face. But just a stone’s throw away, in stark contrast, the breathtaking shapes of the new millennium are evident in the latest architecture and design. It’s no accident that many renowned national and international businesses and organisations have elected The Hague as their home base.

The Hague’s unique location by the North Sea gives it an extra dimension where recreation is concerned.

City of culture

The Hague is ideal for those who love culture. In addition to paintings by Dutch masters like Rembrandt, Vermeer, Jan Steen and Frans Hals, the museums of The Hague offer an extensive collection of works by van Gogh and his contemporaries. The municipal Museum of the city boasts the largest Mondriaan collection in the world. The many art galleries and shops, as well as the antique shops and the antique market are ideal for art aficionados.

The Hague is home base to Nederlands Dans Theater and Residentie Orkest, both renowned around the world. The City's many other theatres offer a wide selection of music, dance and plays. At Scheveningen’s Fortis Circustheater, the famous musicals of the world come to life each night.
Practical information

**Badges:** Congress badges should be worn by all participants at all times during the congress and while visiting the exhibition area. No badge, no entry.

Badges are colour-coded as follows:
- Participants: ESC members: Yellow
- Participants: non-members: White
- Exhibitors: Blue
- Organisers and staff: Red

**Book of abstracts:** You will find the book of abstracts in your congress bag.

**Certificate of attendance:** A certificate of attendance will be available in your personal envelope and will be delivered together with your badge upon arrival.

**Currency:** The currency in the Netherlands is the Euro (€). All Congress fees and rates are charged in Euro. No other currency will be accepted during the Congress.

**Electricity:** Electric appliances in the Netherlands work with 220 volts, ca. 50 Hz and plugs conform to the European system of round pins with two holes.

**Evaluation form:** In order to allow the organisers to learn from past experiences they would be very grateful if you would be willing to give them the necessary feedback. You may be asked to take part in a short interview related to the organisation. An evaluation form is available in your congress bag. Kindly complete the form and return it to the registration desk. The congress organisers appreciate your valuable feedback.

**Exhibit and sponsors:** See also “exhibit and sponsors” later in this final programme. Coffee breaks will be served in the exhibition area (Lobby and Amazon Foyer - 1st Floor). Delegates are encouraged to visit the stands and to recognise the valuable support which these companies have provided towards the congress.
General Assembly: Paid-up members are welcome to attend the General Assembly:
Atlantic, World Forum Convention Center, The Hague
Friday 21 May 2010 at 16:30

Proxy vote forms must be registered with the ESC desk at the Congress at the latest
4 hours before the GA starts. The form will be stamped and returned to the proxy vote
holder. As they enter the GA, they should hand in this stamped form in exchange for a
voting pad, which will allow them to have 2 identical votes.

Hotel accommodation: Hotelmatch is in charge of all hotel reservations and will have
an accommodation desk within the registration area (ground floor) with the aim to help
you with any questions related to accommodation.

Insurance, liability: ESC does not accept liability for individual medical, travel or per-
sonal insurance, and participants are strongly advised to take out their own personal
insurance policies in their country of origin.

Lunches: Participants who register on site for a Meet the Expert session (max. 15 par-
ticipants) or participate to the lunchtime symposium on Thursday will have a lunch box
provided. Lunch boxes will also be provided during the Expert Group sessions (Regis-
tration is needed for the workshop of the Expert Group on non-hormonal methods of
contraception - max 30 participants).

Please find here some lunch facilities:
within the World Forum:
- Famous Tables café (Ground Floor)
- Pangea In House Restaurant (Ground Floor)
within walking distance from the World Forum:
- La Bruschetta - Aert van der Goesstraat 9 - 2582 AH Den Haag
- Da Enzo Marchese - Aert van der Goesstraat 43 - 2582 AJ Den Haag
- Brasserie Meys - Frederik Hendrikliaan 36 - 2582 AX Den Haag
- Lunchroom Tasty - Frederik Hendrikliaan 58 - 2582 BD Den Haag
- Lunchroom Plasman - Frederik Hendrikliaan 106 - 2582 BG Den Haag
- Koemans Snacks en Broodjes - Frederik Hendrikliaan 182 - 2582 BK Den Haag
- Boosty - Frederik Hendrikliaan 294 - 2582 BN Den Haag

Meet the Expert sessions: Meet the Expert sessions are organised on Thursday, from
12:30 - 13:30. Attendance to those sessions is limited to 15 persons maximum. Please
register at the registration desk for these Meet the Expert sessions.

Expert Group on Non-hormonal methods of contraception: please register on site at
the registration desk for the workshop: what are the minimum standards of care that a
healthcare professional (HCP) (in sexual health) in primary/community settings should
provide? This workshop (Friday, 12:25 - 13:25) is limited to 30 persons maximum.

On site registrations:
All amount are payable in euro
ESC members  630
Non-members  730
Nurses, midwives, social workers, counsellors (non-MD), medical students
ESC members  420
Non-members  520
Congress Dinner  100
Extra person(s) attending
the Opening Ceremony and Cocktail  40
the Congress dinner  100

Opening hours of the registration desk :
- Wednesday, May 19  12:00 - 18:30
- Thursday, May 20 08:00 - 18:00
- Friday, May 21 08:30 - 16:00
- Saturday, May 22 08:30 - 12:00

Preview room for invited speakers (Volga 1 - 1st Floor): Speakers are kindly invited to
submit their slides - either on CD-rom, memory stick or laptop - at the latest 60 minutes
before their presentation to the preview room: Volga 1 - 1st Floor, and before their ses-
sion starts. Last minute preview facilities will be available.

Registration package: The registration package for the participants includes:
- admission to the scientific sessions and the exhibition area
- access to the opening ceremony
- abstract book
- final programme
- certificate of attendance
- coffee and tea during breaks
- welcome cocktail (Wednesday May 19, 2010)
- lunch box if registered on site for one of the activities during lunch time

Translation: The official language of the congress will be English. Simultaneous translation is foreseen into Russian:
- plenary sessions in the World Forum Theater
- keynote lectures in the World Forum Theater
- congress sessions in the World Forum Theater and Atlantic.
Some of the Society sessions might be held in the language of the organising country.
Scientific programme

*High standard scientific programme:* the Scientific Committee has endeavoured to put together a high standard, well balanced scientific programme, offering current topics and excellent speakers. To make the programme even more attractive, a considerable proportion will be interactive with the audience.

*Keynote lectures* are plenary sessions which are scheduled for 30 minutes. Leading experts will present specific subjects.

Each congress day starts with a *plenary session* during which no parallel activity is scheduled. An international panel of experts will critically assess the state of scientific knowledge pertaining to a specific topic.

*Congress sessions (State of the art):* in each of these 6 sessions, three or four experts will provide up to date information on a topic, with plenty of opportunity for questions. There will be one selected free communication added to each session.

*Fora* are meant as interactive sessions, introduced by two/three experts in the field and followed by an in depth discussion with the audience.

A *WHO workshop* will teach participants how to implement and apply WHO tools and guidelines.

*Meet the Expert sessions* are scheduled on Thursday and are organised as informal, round table discussions during lunch with a maximum of 15 participants. A variety of topics will be covered. Participants will receive a free lunch box. Please register in advance at the registration desk for these meet the expert sessions.

*ESC Expert Groups* are scheduled on Friday lunch time. They are organised by five Expert Groups and the Nurses/paramedicals special interest group. The format of the sessions may differ from each other. They will focus on the highlights in their area of expertise.

Please register on site at the registration desk for the session of the Expert Group on Non-hormonal methods of contraception: workshop: what are the minimum standards of care that a healthcare professional (HCP) (in sexual health) in primary/community settings should provide? This workshop (Friday, 12:25 - 13:25) is limited to 30 persons maximum.

*Society sessions* are organised by national and international societies or organisations with aims similar to the ESC and will discuss a specific item within their area of interest. Society sessions may be organised in a language other than English.

*Symposia* will be the platform for the pharmaceutical companies.

*Free Communication sessions:* a selection of the submitted free communications are either integrated into the congress sessions or scheduled into separate free communication sessions. Abstracts of selected free communications can be found in the Book of Abstracts.

A *Young Scientist session* aims to provide a special platform for paper presentations by young scientists. The session is primarily targeted at Fellows and Ph.D. students, but the only inclusion criterion was the age < 35 years.

*Poster presentations* are chosen from the submitted abstracts and will carry equivalent scientific status to free communications in the programme. The poster area is in the Basement: the Pacific and Atlantic Foyer. Posters will be on display for the full time of the Congress. Abstracts of selected posters can be found in the Book of Abstracts. Poster can be mounted on Wednesday 19 May, between 12:00 and 19:00. Contact the Poster Managers in the poster area for assistance.
Social programme

Wednesday, May 19, 2010 - Opening Ceremony - 18:00
- Welcome Reception - 19:30

The Opening Ceremony is supported by the City of The Hague.

All participants are warmly invited to join us for the Opening Ceremony that takes place in the main auditorium. It will be an entertaining and eventful introduction to the congress. During the ceremony, the ESC Medal will be awarded for the third time. After the Opening Ceremony, we will officially open the industrial exhibition and invite our delegates to the Welcome Reception. Attendance at the Opening Ceremony and Welcome Reception are complimentary.

Friday, May 21, 2010 - Congress Dinner - 20:00

The 11th ESC Congress will not only be about science, but also about having a good time. Sign up for this event and enjoy a fantastic evening at “Beach Club Doen” in the company of your friends and colleagues. We will offer an exquisite blend of excellent food and entertainment. The dinner site provides you a spectacular view of the sandy beaches of Scheveningen (The Hague). Food will be served as a so-called “walking dinner”, but seating is possible for those who wish. Allow yourself to be surprised by the informal chique. The buses will leave from the entrance of the World Forum Convention Center at 19:30 for Beach Club Doen (Strandweg 9, 2586 JK Scheveningen).

Return transfer to the hotels will be arranged.

Dress code: smart casual

The tickets for this unique event are 100 euro each.

Saturday, May 22, 2010 - Closing session and Award Ceremony - 12:00

......very promising......

The last session but not the least. The ESC Diploma will be awarded. During this Ceremony, presentations will be made to the winners of the 2010 ESC Poster Award, the Public Poster Award, the Best Free Communication Award as well as the winner of the Young Scientist Award. At the end of the Ceremony, we will say goodbye to The Hague with a special Dutch gift and welcome Athens.
### Wednesday, May 19

- **18:00** Opening session
- **19:30** Opening reception

### Thursday, May 20

**World Forum Theater** | **Atlantic** | **Amazon** | **Yangtze** | **Mississippi** | **Everest**
--- | --- | --- | --- | --- | ---
**08:30** | Plenary session 1 | Diversity and SRH in multicultural Europe |  |  |  |
**10:00** | Break and poster viewing |  |  |  |  |
**10:30** | Sponsored symposium | MSD | New formulations in hormonal contraception | Free Communications 1 | Society Session 1 | Faculty of Sexual and Reproductive Healthcare (UK) | Society Session 2 | International Federation of Professional Abortion and Contraception Associates |  |
**12:00** | Sponsored symposium | Bayer Schering Pharma | Meet the Expert sessions | Lunch |  |  |  |  |  |
**14:00** | Sponsored symposium | Bayer Schering Pharma | Congress Session 2 | Determinants of contraceptive behaviour | Workshop | WHO documents and guidelines | Society Session 3 | German Society of Contraception | Society Session 4 | Francophone Society of Contraception |
**15:30** | Break and poster viewing |  |  |  |  |
**16:00** | Keynote 1 | Culture, Communication, Contraception |  |  |  |
**16:30** | Congress session 3 | Prevention: Beyond the Double Dutch | Forum 1 | Contraceptive use: perspective from Europe | Free Communications 2 | Free Communications 3 | Society Session 5 | Association of Reproductive Health Professionals (USA) | Society Session 6 | Italian Society of Contraception |

### Friday, May 21

**World Forum Theater** | **Atlantic** | **Amazon** | **Yangtze** | **Mississippi** | **Everest**
--- | --- | --- | --- | --- | ---
**08:30** | Plenary Session 2 | Evidence based sexual and reproductive health care |  |  |  |
**10:00** | Break and poster viewing |  |  |  |  |
**10:30** | Sponsored symposium | Bayer Schering Pharma | Congress Session 4 | Culture, religion, reproduction and sexuality | Free Communications 4 | Young Scientists | Forum 2 | Contraception and bone | Society Session 7 | Spanish Society of Contraception |
**12:00** | ESC Medal Lecture |  |  |  |  |
**12:15** | Expert group sessions | Lunch |  |  |  |
**13:30** | Keynote 2 | A tribute to Margaret Sanger |  |  |  |
**14:00** | Sponsored symposium | MSD | Congress Session 5 | To bleed or not to bleed | Best Poster Session | Sponsored symposium | Pantanhei Bioscience | Society Session 8 | the Netherlands | SAN/RNG/STI-AIDS | Society Session 9 | Swiss Society of Contraception |
**15:30** | Keynote 3 | Contraception and sexuality: a review |  |  |  |
**16:00** | Break and poster viewing |  |  |  |  |
**16:30** | General Assembly (Members only) |  |  |  |  |

### Saturday, May 22

**World Forum Theater**

- **08:30** Plenary Session 3
- **10:00** Break
- **10:30** Congress Session 6
- **12:00** Closing session and Award ceremony
- **12:45** Congress adjourn

**Expert Group sessions**

- Expert Group on Sexual and reproductive health and education - Atlantic
- Expert Group on STI - Amazon
- Expert Group on Abortion - Yangtze
- Expert Group on Hormonal contraception - Mississippi
- Expert Group on Non-hormonal methods of contraception - Everest (registration on site at the registration desk)
- Nurses/paramedicals special interest group session - Kilimanjaro
Scientific programme

Continuing Medical Education Credits

The European Society of Contraception and Reproductive Health (ESC) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The 11th Congress of the European Society of Contraception and Reproductive Health is designated for a maximum of (or ‘for up to’) 15 hours of European External CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credits to AMA PRA category 1 credit, contact the AMA (www.ama-assn.org).

Wednesday, May 19

World Forum Theater (WFT)

18:00 Opening Session

Cultural programme

Welcome address by the Congress Presidents
R. Beerthuizen (the Netherlands) - R. van Lunsen (the Netherlands)

Welcome address by the ESC President
J. Bitzer (Switzerland)

Welcome address by the deputy Mayor for Public Health, Welfare and Equal Opportunity of The Hague
B. van Alphen (The Netherlands)

ESC Medal Ceremony - J. Lippes (USA)
Introduction, I. Batar (Hungary)

Welcome address by the former State Secretary for Health, Welfare and Sport
M. Bussemaker (The Netherlands)

19:30 Opening Reception

Thursday, May 20

08:30 -10:00 WFT

Plenary session 1
Diversity and sexual/reproductive health (SRH) in multicultural Europe
Chair: J. Bitzer (Switzerland) - R. van Lunsen (the Netherlands)

08:30 • IS-01 Intercultural communication in SRH
V. Claeys (IPPF)

09:00 • IS-02 Virginity: a gender issue?
B. van Moorst (the Netherlands)

09:30 • IS-03 Immigration and contraception: adaptation to different family and cultural models
A. Volpe (Italy)

10:00 - 10:30 Break and poster viewing

10:30 - 12:00 WFT

Sponsored symposium MSD
Oral contraceptives: where we’ve been and where we’re going
Chair: D. Mansour (UK)

10:30 Where we are today
D. Mansour (UK)

10:45 • SP1-2 Estradiol: a new option for Combined Oral Contraceptives
F. Stanczyk (USA)

11:05 • SP1-3 Nomegestrol acetate – a new and different progestin
A. Mueck (Germany)

11:25 • SP1-4 Estradiol and NOMAC – a natural combination
T. Korver (the Netherlands)

Atlantic Congress session 1
New formulations in hormonal contraception
Chair: D. Serfaty (France) - R. Sitruk-Ware (USA)

10:30 • IS-04 Clinical experience with estetrol containing combined OC
H. Coelingh Bennink (the Netherlands)

10:50 • IS-05 Androgen Restored Contraception
H. Termeer (the Netherlands)

11:10 • IS-06 Oestradiol-containing combined contraceptives
G. Merki (Switzerland)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>IS-07</td>
</tr>
<tr>
<td></td>
<td>Selective progesterone receptor modulators</td>
</tr>
<tr>
<td></td>
<td>N. Chabbert-Buffet (France)</td>
</tr>
<tr>
<td>11:50</td>
<td>FC-01</td>
</tr>
<tr>
<td></td>
<td>Preliminary results from a phase III study of the nestorone®/ethinyl estradiol contraceptive vaginal ring: a new, long acting (one year) user controlled contraceptive method</td>
</tr>
<tr>
<td></td>
<td>R. Merkatz (USA)</td>
</tr>
<tr>
<td>10:30</td>
<td>FC-02</td>
</tr>
<tr>
<td></td>
<td>Reducing the buccal dose of misoprostol in mifepristone medical abortion up to 63 days LMP</td>
</tr>
<tr>
<td></td>
<td>T. Tsereteli (Georgia)</td>
</tr>
<tr>
<td>10:43</td>
<td>FC-03</td>
</tr>
<tr>
<td></td>
<td>Awareness and periconceptional use of folic acid</td>
</tr>
<tr>
<td></td>
<td>Results of a European study in women of childbearing age</td>
</tr>
<tr>
<td></td>
<td>A. Von Stenglin (Germany)</td>
</tr>
<tr>
<td>10:56</td>
<td>FC-04</td>
</tr>
<tr>
<td></td>
<td>Follow up and review of 946 sub-dermal Implanon® inserted in the first half of 2008</td>
</tr>
<tr>
<td></td>
<td>H. Mahmoud (UK)</td>
</tr>
<tr>
<td>11:09</td>
<td>FC-05</td>
</tr>
<tr>
<td></td>
<td>Knowledge, attitude and use of emergency contraception improves among young at risk women after community outreach by lay-counselors in a developing country</td>
</tr>
<tr>
<td></td>
<td>P. Steyn (South Africa)</td>
</tr>
<tr>
<td>11:21</td>
<td>FC-06</td>
</tr>
<tr>
<td></td>
<td>Home self-administration of vaginal misoprostol for medical abortion at 50 to 63 days compared with gestation of below 50 days</td>
</tr>
<tr>
<td></td>
<td>H. Kopp Kallner (Sweden)</td>
</tr>
<tr>
<td>11:34</td>
<td>FC-07</td>
</tr>
<tr>
<td></td>
<td>Increasing the proportion of women using Long Acting Reversible Contraception (LARC) within a geographical area in Scotland</td>
</tr>
<tr>
<td></td>
<td>A. Brown (UK)</td>
</tr>
<tr>
<td>11:47</td>
<td>FC-08</td>
</tr>
<tr>
<td></td>
<td>Social inequalities in rates of induced abortion in Spain: a multilevel approach</td>
</tr>
<tr>
<td></td>
<td>G. Perez (Spain)</td>
</tr>
<tr>
<td>10:30</td>
<td>SS1-1</td>
</tr>
<tr>
<td></td>
<td>IUS in women with breast cancer</td>
</tr>
<tr>
<td></td>
<td>K. Gemzell - Danielsson (Sweden)</td>
</tr>
<tr>
<td>11:00</td>
<td>SS1-2</td>
</tr>
<tr>
<td></td>
<td>Obesity and COC</td>
</tr>
<tr>
<td></td>
<td>R.G. Crosignani (Italy)</td>
</tr>
<tr>
<td>11:20</td>
<td>SS1-3</td>
</tr>
<tr>
<td></td>
<td>SLE and contraception for women - Guidelines from WHO Medical Eligibility Criteria and UK Medical Eligibility Criteria</td>
</tr>
<tr>
<td></td>
<td>A. Glasier (UK)</td>
</tr>
<tr>
<td>11:40</td>
<td>SS1-4</td>
</tr>
<tr>
<td></td>
<td>Hormonal contraception and diabetes</td>
</tr>
<tr>
<td></td>
<td>S. Skouby (Denmark)</td>
</tr>
<tr>
<td>10:30</td>
<td>SS2-1</td>
</tr>
<tr>
<td></td>
<td>Medical abortion</td>
</tr>
<tr>
<td></td>
<td>C. Fiala (Austria)</td>
</tr>
<tr>
<td>10:55</td>
<td>SS2-2</td>
</tr>
<tr>
<td></td>
<td>Cervical priming</td>
</tr>
<tr>
<td></td>
<td>R. Moulier (France)</td>
</tr>
<tr>
<td>11:20</td>
<td>SS2-3</td>
</tr>
<tr>
<td></td>
<td>Pain management</td>
</tr>
<tr>
<td></td>
<td>E. Aubény (France)</td>
</tr>
<tr>
<td>11:40</td>
<td>SS2-4</td>
</tr>
<tr>
<td></td>
<td>Myths</td>
</tr>
<tr>
<td></td>
<td>S. Rowlands (UK)</td>
</tr>
</tbody>
</table>

**Yangtze Society Session 1**

Amazon Free Communication Session 1

Abortion, Long-acting reversible contraceptive methods, Emergency contraception, Education and training for family planning professionals

Chair: I. Blidaru (Romania) - E. Lopez Arregui (Spain)

10:30 • FC-02 Reducing the buccal dose of misoprostol in mifepristone medical abortion up to 63 days LMP

10:43 • FC-03 Awareness and periconceptional use of folic acid

Results of a European study in women of childbearing age

A. Von Stenglin (Germany)

10:56 • FC-04 Follow up and review of 946 sub-dermal Implanon® inserted in the first half of 2008

H. Mahmoud (UK)

11:09 • FC-05 Knowledge, attitude and use of emergency contraception improves among young at risk women after community outreach by lay-counselors in a developing country

P. Steyn (South Africa)

11:21 • FC-06 Home self-administration of vaginal misoprostol for medical abortion at 50 to 63 days compared with gestation of below 50 days

H. Kopp Kallner (Sweden)

11:34 • FC-07 Increasing the proportion of women using Long Acting Reversible Contraception (LARC) within a geographical area in Scotland

A. Brown (UK)

11:47 • FC-08 Social inequalities in rates of induced abortion in Spain: a multilevel approach

G. Perez (Spain)

**Yangtze Society Session 1**

Chronic medical conditions and contraception: A transnational take on how conditions are managed in different European countries

Chair: N. Mullin (UK) - D. Cibula (Czech Rep.)

10:30 Introduction

C. Robinson (President FSRH)

10:40 • SS1-1 IUS in women with breast cancer

K. Gemzell - Danielsson (Sweden)

11:00 • SS1-2 Obesity and COC

R.G. Crosignani (Italy)

11:20 • SS1-3 SLE and contraception for women - Guidelines from WHO Medical Eligibility Criteria and UK Medical Eligibility Criteria

A. Glasier (UK)

11:40 • SS1-4 Hormonal contraception and diabetes

S. Skouby (Denmark)

**Mississippi Society Session 2**

Update in abortion care

Chair: M. Parachini (Italy) - A. Verougstraete (Belgium)

10:30 • SS2-1 Medical abortion

C. Fiala (Austria)

10:55 • SS2-2 Cervical priming

R. Moulier (France)

11:20 • SS2-3 Pain management

E. Aubény (France)

11:40 • SS2-4 Myths

S. Rowlands (UK)

**Lunch and poster viewing**

**WFT**

Sponsored symposium Bayer Schering Pharma including lunch (12:15 - 13:45)

Qlaira® - The first estradiol-based pill

Chair: J. Calaf (Spain)

12:15 Introduction

J. Calaf (Spain)

12:20 Rationale for the development of Qlaira®

A. Kubba (UK)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:38</td>
<td>Qlaira® – clinical aspects of a new oral contraceptive</td>
<td></td>
<td>I. Milsom (Sweden)</td>
</tr>
<tr>
<td>12:56</td>
<td>Qlaira® – clinical data on reducing menstrual blood loss</td>
<td></td>
<td>D. Mansour (UK)</td>
</tr>
<tr>
<td>13:16</td>
<td>Bayer Schering Pharma: your expert partner in women's healthcare</td>
<td></td>
<td>Ph. Smits (Germany)</td>
</tr>
<tr>
<td>13:30</td>
<td>Q&amp;A session</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Meet the Expert sessions including lunch (12:30 - 13:30)**
Please register in advance at the registration desk

**Yangtze**
- IS-08 Skills in intercultural sexual health communication
  - B. van Moorst (the Netherlands) - R. van Lunsen (the Netherlands)

**Antarctica**
- IS-09, IS-10 Preventive strategies for ethnic minorities
  - E. Osmanagic (Bosnia Herzegovina) - V. Cupanik (Slovakia)

**Asia**
- IS-11 Skills in sexual health education
  - O. Loeber (the Netherlands) - C. Picavet (the Netherlands)

**Europe 1**
- IS-12 Management of side effects of contraceptives
  - F. Roumen (the Netherlands) - G. Merki (Switzerland)

**Europe 2**
- IS-13 Sexual counselling in family planning consultations
  - J. Alder (Switzerland) - B. Pehlivanov (Bulgaria)

**Mississippi**
- IS-14 Future of contraception
  - Ph. Bouchard (France) - R. Sitruk-Ware (USA)

**North America**
- IS-15 Media: an important tool
  - B. Pinter (Slovenia) - E. Erös (Hungary)

**Central America**
- IS-16 Preventive strategies for adolescence
  - K. Sedlecky (Serbia) - D. Apter (Finland)

**South America**
- IS-17 Emergency contraception: the lack of impact on abortion rates
  - A. Webb (UK) - B. Frey Tirri (Switzerland)

**Everest 1**
- IS-18 How to measure quality of life
  - M. A. Gomez (Spain) - I. Lete (Spain)

**Kilimanjaro 1**
- IS-19, IS-20 How to deal with repeat abortion
  - A. Verougstraete (Belgium) - V. Yaglov (Russia)

**Everest 2**
- IS-21 Peer education of adolescents
  - E. Aubény (France) - S. Tschudin (Switzerland)

**Kilimanjaro 2**
- IS-22 Practical aspects of medical abortion
  - K. Gemzell-Danielsson (Sweden) - H. Missey-Kolb (France)

**Summit Foyer**
- IS-23 Cancer risks and contraception
  - D. Lazaris (Greece) - A. Mueck (Germany)

**Atlantic**
- IS-24 Determinants of contraceptive behaviour
  - Chair: C. McNicholas (Ireland) - H. Guner (Turkey)

**Congress Session 2**
- IS-25 Computer assisted decision making on contraceptive use
  - R. French (UK)
- IS-26 Information about SRH: sources used by teenagers
  - D. Apter (Finland)
- IS-27 Determinants of user failures
  - C. Moreau (France)
- IS-28 Lessons from behavioural medicine
  - J. Bitzer (Switzerland)
- IS-29 The potential impact of satisfying the unmet need for contraception
  - G. Sedgh (USA)

---

Thursday, May 20
Amazon Workshop
WHO documents and guidelines

14:00 • IS-28 International perspective on the need for guidelines
**P. van Look (Switzerland)**

14:30 • IS-29 Regional experience of implementation of WHO tools and guidelines in the area of SRH
**G. Lazdane (WHO Europe)**

15:00 Adaptation and application of WHO guidelines in UK
**C. Smith (UK)**

Yangtze Society Session 3:
German Society of Contraception
Session will be held in German
Chair: T. Rabe (Germany) - C. Liedtke (Germany)

14:00 OC and cancer risk
**C. Liedtke (Germany)**

14:15 • SS3-2 Contraception – communication in special risk populations
**A. Mueck (Germany)**

14:30 • SS3-3 Endometriosis and hormonal contraception
**A.E. Schindler (Germany)**

14:45 • SS3-4 New aspects on natural family planning – myths and facts
**P. Frank-Herrmann (Germany)**

15:00 • SS3-5 The sexual life of German medical students: Investigation of the prevalence of sexual dysfunction and the impact of contraception
**L.M. Wallwiener (Germany)**

15:15 • SS3-6 New developments in hormonal contraception for women
**T. Rabe (Germany)**

Mississippi Society Session 4:
Société Francophone de Contraception (SFC)
Session will be held in French

Intérêt des contraceptions réversibles de longue durée actuelles et futures
Présidents: H. Chelli (Tunisie), D. Serfaty (France)

14:00 • SS4-1 Les méthodes de contraception de longue durée actuelles et futures
**D. Serfaty (France)**
**Discutants: J.F. Meyé - J.C. Moreau**

14:22 • SS4-2 L’anneau vaginal annuel à la nestorone
**R. Sitruk-Ware (Etats-Unis)**
**Discutants: B. Dao - M. Traoré**

14:44 Les contraceptifs estroprogestatifs injectables mensuels
**P. Hall (OMS)**
**Discutants: N. Homasson - R. Dreyfus**

15:06 Stérilisation ou contraception de longue durée?
**J. Berubé (Canada)**
**Discutants: Y. Hyjazi - M. Brincat**

Discussion générale animée par J. Abboud (Liban), M.O. Abdelkader (Mauritanie), J. Bitzer (Suisse), M. Bouzekrini (Algérie), U. Gaspard (Belgique), B. Guifo-Tagné (Cameroun), D. Hinh (Vietnam), N. Ogowet-Igumu (Gabon), C. Welfens-Ekra (Côte d’Ivoire), M. Yacoubi (Maroc).

15:30 - 16:00 Break and poster viewing

Amazon Sponsored Lecture Laboratoire HRA Pharma
• SP2-1 Ellaone® Ulipristal Acetate, the new reference for emergency contraception - Higher efficacy and increased time window for use: clinical evidence
**A. Brown (UK)**

WFT Keynote Lecture 1
Chair: D. Lazaris (Greece) - K. Petersen (Denmark)
• IS-31 Culture, Communication, Contraception
**R. van Lunsen (the Netherlands)**

WFT Congress Session 3
Prevention: beyond the ‘double Dutch’
Chair: M. Lech (Poland) - D. Apter (Finland)

16:30 • IS-32 Policies for the prevention of unintended pregnancies in Europe
**M. Larsson (Sweden)**

16:50 • IS-33 Combined prevention of unintended pregnancy and STI
**G. Lazdane (WHO)**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:10</td>
<td>IS-34</td>
<td>What about boys?</td>
<td>M. Ekstrand (Sweden)</td>
</tr>
<tr>
<td>17:30</td>
<td>IS-35</td>
<td>How to deal with sexual coercion and violence?</td>
<td>B. Schei (Norway)</td>
</tr>
<tr>
<td>17:50</td>
<td>FC-10</td>
<td>Risk factors for men to become involved in repeated abortions</td>
<td>M. Makenzius (Sweden)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atlantic Forum 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• IS-36</td>
<td>Contraceptive use: perspective from Europe</td>
<td>K. Sedlecký (Serbia) - T. Bombas (Portugal)</td>
</tr>
<tr>
<td>16:30</td>
<td>FC-11</td>
<td>Early use effects on the risk of venous thromboembolism after initiation of oral contraceptive use</td>
<td>J. Dinger (Germany)</td>
</tr>
<tr>
<td>16:43</td>
<td>FC-12</td>
<td>Sexuality and sexual behavior of Lithuanian post-menopausal women</td>
<td>B. Zilaitiene (Lithuania)</td>
</tr>
<tr>
<td>16:56</td>
<td>FC-13</td>
<td>Intrauterine devices and the risk of uterine perforations: interim results from the EURAS-IUD study</td>
<td>K. Heinemann (Germany)</td>
</tr>
<tr>
<td>17:09</td>
<td>FC-14</td>
<td>Sexual and reproductive health behaviors in the United States: new data from the National Survey of Family Growth</td>
<td>L. Finer (USA)</td>
</tr>
<tr>
<td>17:22</td>
<td>FC-15</td>
<td>Mother knows best? A survey on contraception use and attitudes among mothers and their daughters</td>
<td>D. Seidman (Israel)</td>
</tr>
<tr>
<td>17:35</td>
<td>FC-16</td>
<td>Breast cancer risk associated with the use of levonorgestrel-containing intrauterine devices compared to copper intrauterine devices</td>
<td>J. Dinger (Germany)</td>
</tr>
<tr>
<td>17:43</td>
<td>FC-17</td>
<td>Persistent use of withdrawal in Turkey: 1978-2008</td>
<td>L. Koc (Turkey)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yangtze Free Communication Session 3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• FC-18</td>
<td>HPV diagnosis: is there an impact on women's sexual and mental health?</td>
<td>N. Salakos (Greece)</td>
</tr>
<tr>
<td></td>
<td>• FC-19</td>
<td>Reducing serious infection following medical abortion</td>
<td>J. Trussell (USA)</td>
</tr>
<tr>
<td>16:56</td>
<td>FC-20</td>
<td>On the sword and the sheath. Blood loss and pain at first coitus in women from different cultural backgrounds.</td>
<td>O. Loeber (the Netherlands)</td>
</tr>
<tr>
<td>17:09</td>
<td>FC-21</td>
<td>An oral contraceptive comprising estradiol valerate/dienogest is effective in the treatment of heavy and/or prolonged menstrual bleeding: a pooled analysis</td>
<td>I. Fraser (Australia)</td>
</tr>
<tr>
<td></td>
<td>• FC-22</td>
<td>‘Repeat Abortion’ - defining the problem and addressing the issue</td>
<td>A. Furedi (UK)</td>
</tr>
<tr>
<td></td>
<td>• FC-23</td>
<td>Can the bleeding pattern during consecutive use of the LNG-IUS be predicted?</td>
<td>K. Gemzell-Danielsson (Sweden)</td>
</tr>
<tr>
<td></td>
<td>• FC-24</td>
<td>Complications in the removal of subdermal contraceptive implants for seven years. Migration of the implants</td>
<td>J.F. Garrido (Spain)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mississippi Society Session 5: Association of Reproductive Health Professionals (ARHP)</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>SSS-1</td>
<td>Emergency contraception</td>
<td>P. Rodriguez (USA)</td>
</tr>
<tr>
<td>17:15</td>
<td>SSS-2</td>
<td>The impact of environmental contaminants on reproductive health</td>
<td>P. Rodriguez (USA)</td>
</tr>
</tbody>
</table>
Friday, May 21

08:30 -10:00  WFT  Plenary Session 2 : Evidence based sexual and reproductive health care
Chair: P. G. Crosignani (Italy) - R. Beerthuizen (the Netherlands)

08:30 • IS-37 Building research into clinical practice
M. Kishen (UK)
09:00 Guidelines in family planning
J. Bitzer (Switzerland)
09:30 • IS-39 Critical appraisal of contraceptive research
I. Sivin (USA)

10:00 - 10:30 Break and poster viewing

10:30 - 12:00 WFT  Sponsored Symposium Bayer Schering Pharma
Benefits and risks of oral contraception: responsible prescribing and counselling
Chair: S. Shapiro (South Africa) - M. Cronin (Germany)

10:30 Introduction
S. Shapiro (South Africa)
10:40 Overview of the benefits and risks of oral contraceptive use
A. Szarewski (UK)
11:00 Cardiovascular side effects of OC use
J. Dinger (Germany)
11:25 Responsible OC prescribing
D. Mansour (UK)
11:45 Q&A session
11:55 Summary
S. Shapiro (South Africa) - M. Cronin (Germany)

Atlantic  Congress Session 4
Culture, religion, reproduction and sexuality
Chair: O. Loeber (the Netherlands) - D. Seidman (Israel)

10:30 • IS-40 Religion and sexuality
W. Gianotten (the Netherlands)
10:50 Power, politics and contraception
D. Patel (UK)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:10</td>
<td>IS-42</td>
<td>How to explain the differences in contraceptive use in Europe</td>
<td>J. Bitzer (Switzerland)</td>
</tr>
<tr>
<td>11:30</td>
<td>FC-25</td>
<td>Exploring the linkages between Gender Based Violence (GBV) and spread of HIV/Sexually Transmitted Infection (STI) among women in Bangalore city, India</td>
<td>G.K. Dayaprasad (India)</td>
</tr>
<tr>
<td>10:30</td>
<td>FC-26</td>
<td>Hormonal contraception and female sexual desire: a randomized within-subject crossover study with a low-dose combined oral contraceptive, a progestin-only-pill, and the vaginal ring</td>
<td>E. Elaut (Belgium)</td>
</tr>
<tr>
<td>10:43</td>
<td>FC-27</td>
<td>Knowledge of HPV and attitudes to HPV vaccination among Swedish high school students</td>
<td>M. Gottvall (Sweden)</td>
</tr>
<tr>
<td>10:56</td>
<td>FC-28</td>
<td>Gender based violence (GBV) - an important factor influencing high risk sexual behavior among transgenders in Bangalore city, India</td>
<td>G.K. Dayaprasad (India)</td>
</tr>
<tr>
<td>11:09</td>
<td>FC-29</td>
<td>In vitro spermicidal activity of peptides from amphibian skin: dermaseptin S4 and derivatives</td>
<td>A. Zairi (Tunisia)</td>
</tr>
<tr>
<td>11:21</td>
<td>FC-30</td>
<td>Unexpected large perinatal health inequalities in an urban, multi-ethnic population in the Netherlands</td>
<td>J. Poeran (The Netherlands)</td>
</tr>
<tr>
<td>11:34</td>
<td>FC-31</td>
<td>Emergency Contraception (EC): how it works in Ukraine</td>
<td>A. Yermachnko (Ukraine)</td>
</tr>
<tr>
<td>11:47</td>
<td>FC-32</td>
<td>Paradoxical messages on sexuality - reflections on the impact of pornography on young people among personnel at schools and youth clinics</td>
<td>M. Mattebo (Sweden)</td>
</tr>
</tbody>
</table>

**Amazon**

Free Communication Session 4 - Young scientist session  
Chair: S. Randall (UK) - H. Satiroglu (Turkey)

10:30 • FC-26 Hormonal contraception and female sexual desire: a randomized within-subject crossover study with a low-dose combined oral contraceptive, a progestin-only-pill, and the vaginal ring  
E. Elaut (Belgium)

10:43 • FC-27 Knowledge of HPV and attitudes to HPV vaccination among Swedish high school students  
M. Gottvall (Sweden)

10:56 • FC-28 Gender based violence (GBV) - an important factor influencing high risk sexual behavior among transgenders in Bangalore city, India  
G.K. Dayaprasad (India)

11:09 • FC-29 In vitro spermicidal activity of peptides from amphibian skin: dermaseptin S4 and derivatives  
A. Zairi (Tunisia)

11:21 • FC-30 Unexpected large perinatal health inequalities in an urban, multi-ethnic population in the Netherlands  
J. Poeran (the Netherlands)

11:34 • FC-31 Emergency Contraception (EC): how it works in Ukraine  
A. Yermachnko (Ukraine)

11:47 • FC-32 Paradoxical messages on sexuality - reflections on the impact of pornography on young people among personnel at schools and youth clinics  
M. Mattebo (Sweden)

**Yangtze**

Contraception and bone: should we worry?  
P. Bouchard (France) - K. Schaudig (Germany) - P. Rodriguez (USA)

**Mississippi**

Society Session 7: Spanish Society of Contraception (SEC)  
Session will be held in Spanish  
Chair: E. de la Viuda García (Spain)

10:30 • SS7-1 The influence of the beginning of sexual relations and of contraception in the Spanish women's life  
J.V. González Navarro (Spain)

10:52 • SS7-2 The influence of mass media in the diffusion of the contraceptive methods  
I. Lele Lasa (Spain)

11:14 • SS7-3 Updating tromboembolism and its relationship with combined hormonal contraceptives  
F. Martínez San Andrés (Spain)

11:36 • SS7-4 Contraception and quality of life  
E. Pérez Campos (Spain)

12:00 - 12:15 WFT • IS-45 ESC Medal Lecture  
J. Lippes (USA)

12:15 - 13:30 Lunch and poster viewing

**Atlantic**

Forum: Standards of sexual education across Europe  
Moderators: O. Loeber (the Netherlands) - S. Reuter (UK)

Topics (among others): when to start sexuality education, who should provide this, what should the contents be, what is the role of policy makers, does it make a difference in what country one operates?

Participants, interested in providing sexuality education and policy makers are invited to join this discussion.
Amazon     2. Expert Group on STI
Contraception & STIs in women over 40
This group will review a topic that is often overlooked. These
women may have missed out on sex education but put
themselves at risk of unwanted pregnancies and sexually
acquired infections.

- IS-47
  Epidemiology
  B. Frey Tirri (Switzerland)
- IS-48
  STI prevention
  P. Horner (UK)
- IS-49
  Contraceptive options
  P.A. Mardh (Sweden)

Yangtze     3. Expert Group on Abortion
Workshop: Remaining barriers to safe abortion and
possible solutions
Chair: E. Aubény (France)

- IS-50
  12:25 Problems-remaining barriers
  C. Fiala (Austria)
  12:40 Advances in recent years
  K. Guthrie (UK)
- IS-52
  12:55 Possible solutions
  K. Gemzell-Danielsson (Sweden)
  13:05 Discussion

Aims: to explore existing barriers in Europe to quality abortion
care and review possible solutions
Objectives: to provide participants with information which
may positively influence their practice at home and to identify
issues which could lead to national/international clinical/
scientific collaboration to improve evidence based high
quality abortion care.
What can participants expect? Sharing international knowledge
of good and poor practice with opportunities to learn something
positive to take home to improve local abortion care.

Mississippi  4. Expert Group on Hormonal contraception
Male fertility control - where are we?
Chair: D. Serfaty (France) - J.-J. Amy (Belgium)

12:30 • IS-53  Why do we need male contraceptive methods?
  K. Vogelsong (WHO)
12:45 • IS-54  Hormonal Contraceptive methods for men today and tomorrow
  E. Nieschlag (Germany)
13:00 • IS-55  Future technologies for male contraception
  R. Sitruk-Ware (Population Council)
13:15 Discussion
  S. Skouby (Denmark)

Everest     5. Expert Group on Non-hormonal methods of contraception
Workshop: What are the minimum standards of care that
a healthcare professional (HCP) (in sexual health) in
primary/community settings should provide?
Chair: I. Batar (Hungary) - P. Weiss (Czech Republic)

Please register in advance at the registration desk (max 30 p.)

   Moderators: S. Jones (Practicing nurse, UK), J. Alder
               (Psychosexual counsellor, Switzerland), C. McNicholas
               (GP, Ireland), R. Beerthuizen (Gynecologist, the Netherlands)

Learning objectives:
by the end of the workshop the participants will:
  * understand and be able to provide basic advice and information
    on all non hormonal methods;
  * recognise which methods the HCP can provide in his/her
    practice. This would be dependant on what training the HCP has
    had or what training the HCP may need, what facilities are present,
    what the local arrangements are;
  * when and/or for what methods the HCP should refer the client
    to a specialist

Kilimanjaro Nurses/midwives/paramedics special interest group
meeting
Chair: S. Mehigan (UK)

The ESC would like to invite all nurses/midwives/paramedics
to this meeting to discuss their role within the ESC. This
meeting will be in English.

The ESC has always included non doctors as members,
recognising the multidisciplinary focus of work within sexual
health. To date, this group is not represented on the Board or in
any of the Expert Groups.
So, how can we best raise the profile of nurses/midwives/paramedics? Should there be a separate group or more encouragement to be involved within the current committees and groups? Why would we want a separate group? What would we call it? What would be its role? Who could be members? What is the role of nurses/midwives/paramedics in different countries?

13:30 - 14:00 WFT  Keynote Lecture 2
Chair: M. Tarasova (Russia) - K. Sedlecky (Serbia)

• IS-57 A tribute to Margaret Sanger
  J.-J. Amy (Belgium)

14:00 - 15:30 WFT  Sponsored Symposium MSD
Making informed CHOICES in contraception: the role and importance of counseling
Chair: J.M. Foidart (Belgium)

14:00  Contraception for the individual woman
  J.M. Foidart (Belgium)
14:10  Contraceptive use and the importance of contraceptive counseling
  D. Mansour (UK)
14:35  Studies of post-counseling contraceptive use
  F. Palma (Portugal)
14:55  Preliminary results from the CHOICE data
  A. Yeshaya (Israel)

Atlantic
Congress Session 5
To bleed or not to bleed; tailor made bleeding patterns in contraception
Chair: A. Glasier (UK) - I. Batar (Hungary)

14:00 • IS-58  What women want
  H. Critchley (UK)
14:20  How to manage bleeding problems during contraceptive use?
  D. Serfaty (France)
14:40 • IS-60  Contraceptives for menstrual disorders
  R. Hurskainen (Finland)
15:00 • IS-61  Changing the 21/7 paradigm in contraceptive regimen
  A. van Heusden (the Netherlands)

15:20 • FC-33  Contraceptive health education research program in women considering combined hormonal contraception: CHOICE (Contraceptive Health Research of Informed Choice Experience) results from the Ukraine
  V. Kaminsky (Ukraine)

Amazon
Best Poster Session
14:00 - 14:30  Chair: S. Randall (UK) - N. Salakos (Greece)

Amazon
Sponsored symposium Pantarhei Bioscience
Androgens and the Pill
Chair: B. Fauser (the Netherlands) - H. Coelingh Bennink (the Netherlands)

14:30  Endocrine effects of the pill on androgen metabolism
  Y. Zimmerman (the Netherlands)
14:50  Effect of the pill on sexual function
  E. Laan (the Netherlands)
15:10  Clinical effects of adding DHEA to the pill
  F. Roumen (the Netherlands)

Yangtze
Society Session 8: Rutgers Nisso Group, STI AIDS Netherlands, and the Dutch Foundation for Contraception
Communication about sexuality and contraception in a multicultural context
Chair: C. Wijsen (the Netherlands) - P. Scholten (the Netherlands)

14:00 • SS8-1  Secrecy vs communication and risk vs trust in the use of vaginal microbicides in Africa
  R. Pool (Spain)
14:30 • SS8-2  Communication between partners about sexuality and contraception
  M. De Neef (the Netherlands)
15:00 • SS8-3  Reproduction and STI/HIV prevention strategies of migrant Women in the Netherlands
  I. Shiriqinda (the Netherlands)
Mississippi  Society Session 9:
Swiss Society of Contraception
Special considerations in contraception
Chair: G. Merki-Feld (Switzerland) – J. Bitzer (Switzerland)

14:00 • SS9-1  Combined hormonal contraception - its significance relative to other treatment options for women with premenstrual symptoms?
S. Tschudin (Switzerland)

14:30 • SS9-2  Less increase in bone density in young users of contraceptive pills – myth or truth?
G. Merki-Feld (Switzerland)

15:00 • SS9-3  Progestagen-only contraception - an alternative to combined pill preparations in women with increased risk for venous and arterial thrombosis?
K. Schaudig (Germany)

Saturday, May 22

08:30 -10:00  WFT  Plenary Session 3
Education and training for family planning professionals
Chair: S. Mann (UK) - F. Roumen (the Netherlands)

08:30  The ESC course
M. Lech (Poland)

08:52  Top five cited papers (in the EJCIRCH) and how to put them into clinical practice
J.-J. Amy (Belgium)

09:14 • IS-65  A new curriculum for specialists in SRH
A. Gebbie (UK)

09:36 • IS-66  E-learning in SRH
C. Wilkinson (UK)

10:00 - 10:30  Break

10:30 - 12:00  WFT  Congress Session 6
Contraception and gynaecological disease
Chair: I. Lete (Spain) - I. Blidaru (Romania)

10:30  Hormonal contraception and endometriosis
G. Dunselman (the Netherlands)

10:50  Contraception for women with uterine myomas
H.J. Ahrendt (Germany)

11:10 • IS-69  PCO, metabolic syndrome and contraception
S. Skouby (Denmark)

11:30  Contraception after cancer
D. Cibula (Czech Rep.)

11:50 • FC-34  Uterine volume and menstrual patterns in users of LNG-IUS intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas. A cohort prospective study of 8 years.
J. Magalhaes (Brazil)
Closing Session and Award Ceremony

Cultural programme

Congress Highlights
J. Bitzer (Switzerland)
R. van Lunsen (the Netherlands)
R. Beerthuizen (the Netherlands)

The Hague Declaration
J. Bitzer (Switzerland)

ESC Diploma Ceremony - E. Aubény (France)
Introduction, A. Webb (UK)

Young Scientist Award
Best Poster Awards
Public Poster Award
Ballot Public Poster Award (random draw)
Best Free Communication Award
Introduction, D. Apter (Finland)

A tribute to Aletta Jacobs
S. Wieringa, director “Aletta, Institute for women’s history”

Invitation 12th ESC Congress, Athens, Greece
D. Lazaris (Greece)

Special Dutch gift

Exhibit and sponsors

The exhibition area is situated on the first floor: Lobby and Amazon Foyer.

Coffee breaks will be served in the exhibition area. Delegates are encouraged to visit the exhibition stands and to recognise the valuable financial support which these companies have provided towards the congress.

Opening hours exhibit:
- Wednesday, May 19 18:00 - 21:00
- Thursday, May 20 08:30 - 18:00
- Friday, May 21 08:30 - 16:30
- Saturday, May 22 08:30 - 12:30

Major sponsors:

Bayer Schering Pharma
MSD

Sponsors:
Eurim-Pharm
Found Animals Foundation
Gedeon Richter
HRA Pharma
Informa Healthcare
Kessel
Nordic Pharma
Pantarhei Bioscience
Prosan International
Time Research Limited
Wisepress Online Bookshop
1. Name of the medicinal product

Qlaira®

2. Qualitative and quantitative composition

Each tablet contains:
- 2 mg estradiol valerate
- 3 mg dienogest

3. Pharmaceutical form

Film-coated tablets

4. Clinical particulars

4.1 Therapeutic indications

Oral contraception.

4.2 Posology and method of administration

How to take Qlaira®

• Continue with tablet-taking in the normal way if the woman has missed any tablet(s) within the first 5 days of a new wallet.

If any tablets from a wallet are missed:

3 – 7 medium red tablets
3 – 7 light yellow tablets

If any tablets from a new wallet are missed:

18 – 24 light yellow tablets

• Stop immediately if there is any reason to discontinue COC use (e.g. if a barrier method such as a condom) have to be used according to the following principles:

- If the woman has missed one tablet during day 1 to 5 of a new wallet:
  - Take missed tablet immediately and the following tablet that day (in the event of late active tablet-taking, the next tablet should be taken as soon as possible).

- If the woman has missed one tablet during day 5 to 21 of a new wallet:
  - Take missed tablet immediately and the following tablet that day (in the event of late active tablet-taking, the next tablet should be taken as soon as possible).

- If the woman has missed one tablet during day 21 to 28 of a new wallet:
  - Take missed tablet immediately and the following tablet that day (in the event of late active tablet-taking, the next tablet should be taken as soon as possible).

- If the woman has missed one tablet during day 28 to 4 weeks:
  - Take missed tablet immediately and the following tablet that day (in the event of late active tablet-taking, the next tablet should be taken as soon as possible).

4.3 Contraindications

Combined oral contraceptives (COCs) should not be used in the presence of any of the conditions listed below. Should any of the conditions appear for the first time during COC use, the product should be stopped immediately.

Venous thrombosis present or history (deep venous thrombosis, pulmonary embolism). Articular thrombosis present in or history (e.g. myocardial infarction) or perinatal complications (e.g. anogenital or transient ischemic attack).

Cerebrovascular accident present or in history. Presence of severe or multiple risk factors for venous or arterial thrombosis, such as APOE-ε4, antithrombin III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies or antithrombin antibodies, lupus anticoagulant. Pancreatitis or a history thereof if associated with severe hyperlipidaemia. Presence or history of severe hepatic disease as long as liver function values have not returned to normal. Presence or history of liver tumours (benign or malignant). Known or suspected ovarian or uterine disorders, which may obstruct the Fallopian tubes.

4.4 Special warnings and precautions for use

Warnings for users

If any of the conditions/risk factors mentioned below are present, the benefits of COC use should be weighed against the possible risks for the individual woman and discussed with the woman before she decides to start taking it. In the event of aggravation, exacerbation or appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide whether COC use should be discontinued.

4.5 Overdose

In the event of an overdose, the following measures are recommended:

- Induce vomiting (if possible and it is performed within 2 hours).
- Give activated charcoal or a cathartic.
- Seek medical advice immediately.

5. Preclinical safety studies

There is no information available on the risk of congenital anomalies associated with this medicinal product.

6. Posology and method of administration

6.1 Administration

6.2 Overdose

6.3 For use in the paediatric population

7.4.6 Women should be advised to start at day 21 to 28 after delivery or second-trimester abortion (if the next injection would be due), but should in all of these cases be advised to additionally use a condom (e.g. a barrier method such as a condom) have to be used according to the following principles:


**Systemic Organ Class**

Infections and infestations

Fungal infections. 
Viral infections. 
Bacterial infections. 
Vaginal infection.

Cardiopulmonary, hepatic and peripheral vascular disorders. 
Inflammatory, allergic and autoimmune disorders, Acute infectious and parasitic diseases. 
Ventriculitis. 
Ventriculitis. 
Ventriculitis.

**4.5 InTeracTion WiTh oTher Substances**

The pharmacokinetic interactions of estradiol and dienogest with certain other active substances. Accordingly, plasma and tissue concentrations may either increase or decrease. The potential for interactions with estradiol is depicted in the table below.

<table>
<thead>
<tr>
<th>Interaction</th>
<th>Increase</th>
<th>Decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ketoconazole</td>
<td>186%</td>
<td>57%</td>
</tr>
</tbody>
</table>

**4.6 Metabolism and Excretion**

The hepatic tumour should be considered in the differential diagnosis when severe upper abdominal pain, loss of appetite, or signs of intra-abdominal hemorrhage occur in women taking COCs. The possibility of anticoagulant therapy should also be taken into account. COC users with liver dysfunction or are currently using COCs, which are discussed in section 4.4 Special warning and precautions for use:

- Women with hereditary angioedema exogenous estrogens may induce or exacerbate symptoms of angioedema.
- Acute or chronic disorders of liver function may exacerbate the clinical signs of liver disease.
- An alteration of liver function may mask the symptoms of serious liver disorders.
- In women with history of cholestasis-associated hepatitis or porphyria, systemic lupus erythematosus, herpes gestationis, Sydenham’s chorea, focal nodular hyperplasia of the liver, allergic reactions, and drug-related disorders, the use of COCs should be avoided.

**4.7 effecTs on Psychiatric Properties**

The observed pattern of increased risk may be due to an earlier diagnosis of breast cancer in COC users, the biological effects of COCs or a combination of both. The increased risk has not been observed in all studies and is not confirmed clinically or statistically in comparison to the controls.

**4.9 oVerdose**

**References**

For a complete medical history (including past medical history), see table on the next page!
becomes metabolized before entering the systemic circulation. The main metabolites are estrone, estrone sulfate and estrone glucuronide. Distribution: In serum 38% of estradiol is bound to SHBG, 60% to albumin and 2 - 3% circulate in free form. Estradiol can slightly induce the serum concentrations of SHBG in a dose-dependent manner. On day 21 of the treatment cycle, SHBG was approximately 124% of the baseline, it decreased to about 141% of the baseline by day 28 (end of placebo phase). An apparent volume of distribution of approximately 1.2 l/kg was determined after iv. administration. Elimination: The plasma half-life of circulating estradiol is about 90 min. After oral administration however, the situation differs. Because of the large circulating pool of estrogen sulfates and glucuronides, as well as enterohepatic recirculation, the terminal half-life of estradiol after oral administration represents a composite parameter which is dependent on all of these processes and is on the range of about 13 - 20 h. Estradiol and its metabolites are mainly excreted in urine, with about 10% being excreted in the stool. Steady-state conditions: Pharmacokinetics of estradiol are influenced by SHBG levels. In young women, the measured estradiol plasma levels are a composite of the endogenous estradiol and the estradiol generated from Qlaira®. During the treatment phase of 2 mg estradiol valerate + 3 mg dienogest, maximum and average estradiol serum concentrations at steady state are 68.0 pg/ml and 51.6 pg/ml, respectively. Throughout the 28 day-cycle, stable minimum estradiol concentrations were maintained and ranged from 29.7 pg/ml to 64.7 pg/ml. Special Populations: Pharmacokinetics of Qlaira® were not investigated in patients with impaired renal or liver function. 5.3 PRECLINICAL SAFETY DATA Preclinical data reveal no special risks for humans based on conventional studies of repeated dose toxicity, genotoxicity, and toxicity to reproduction. A carcinogenicity study with dienogest in mice and a more limited study in rats showed no increase in tumours, however, it is well known that due to their hormonal action, sex steroids can promote the growth of certain hormone-dependent tissues and tumours. 6. PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS

Active film-coated tablets

Tablet core:
- Lactose monohydrate
- Maize starch
- Pregelatinized maize starch
- Povidone K25 (E1201)
- Magnesium stearate (E572)

Tablet coating:
- Hypromellose type 2910 (E464)
- Macrogol 6000
- Talc (E553b)
- Titanium dioxide (E171)
- Iron oxide red (E172)
- and/or
- Iron oxide yellow (E172)

Lactose monohydrate
Maize starch
Pregelatinized maize starch
Povidone K25 (E1201)
Magnesium stearate (E572)

6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE 5 years. 6.4 SPECIAL PRECAUTIONS FOR STORAGE This medicinal product does not require any special storage conditions. 6.5 NATURE AND CONTENTS OF CONTAINER Transparent PVC/Aluminium blister in a cardboard wallet Presentation pack sizes: 1 x 28 film-coated tablets, 3 x 28 film-coated tablets, 6 x 28 film-coated tablets, each wallet (28 film-coated tablets) contains in the following order: 2 dark yellow tablets and 5 medium red tablets and 17 light yellow tablets and 2 dark red tablets and 2 white tablets. Not all pack sizes may be marketed. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL Any unused product or waste material should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER <assigned locally> 8. MARKETING AUTHORISATION NUMBER(S) <assigned locally> 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION <assigned locally> 10. DATE OF REVOCATION OF THE TEXT <assigned locally>

Please note! For current prescribing information refer to the package insert and/or contact your local Bayer Schering Pharma Organisation, Bayer Schering Pharma AG, European Business Unit Women’s Healthcare, 13342 Berlin, Germany, www.bayerscheringpharma.de

Bayer HealthCare
Bayer Schering Pharma
Qlaira®: Oral contraception with estradiol valerate and dienogest

Qlaira® is the first pill to deliver estradiol. This is uniquely combined with dienogest, a progestin with endometrial focus.¹-³


Please go to page 37 for full SPC.